Glucagon-like peptide 1 receptor agonists (GLP1RAs) are established treatments for metabolic disorders such as type 2 diabetes mellitus and obesity, and are also being explored in the treatment of metabolic-associated fatty liver disease and neurodegenerative diseases. These drugs are known to have an anti-inflammatory effect; however, whether this effect was solely the results of GLP1RAs reducing blood levels of glucose and body weight or whether there were direct interactions between GLP1R and the immune system was unclear. A study published in Cell Metabolism now builds on previous work to address this question.

中文翻译：

---

脑免疫网络：GLP1 受体的作用

胰高血糖素样肽 1 受体激动剂 (GLP1RA) 是治疗 2 型糖尿病和肥胖等代谢性疾病的既定疗法，并且也在探索治疗代谢相关的脂肪肝疾病和神经退行性疾病。已知这些药物具有抗炎作用；然而，这种效应是否仅仅是 GLP1RA 降低血糖和体重的结果，或者 GLP1R 与免疫系统之间是否存在直接相互作用尚不清楚。现在发表在《细胞代谢》上的一项研究以之前的工作为基础来解决这个问题。